Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice
Among the differentiated forms of thyroid cancer, the least favorable clinical prognosis is observed in radioiodine-refractory differentiated thyroid cancer. The next step in the treatment of such patients is effective and potential toxicity multi-kinase inhibitors. Often, patients with refractory r...
Saved in:
| Main Authors: | P. O. Rumyantsev, E. V. Borodavina, S. I. Kutukova, E. B. Vasilyeva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-11-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/673 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01) -
Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?
by: E. V. Borodavina, et al.
Published: (2024-12-01) -
Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01) -
Observation and treatment of patients with progressive metastatic differentiated thyroid cancer after establishment of radioiodine refractoriness
by: E. V. Borodavina, et al.
Published: (2024-08-01) -
Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study)
by: Giulia Puliani, et al.
Published: (2025-04-01)